Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...
Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...
Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 ...
Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis ...
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
First for Women on MSN5d
La La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ...
UCB, a global biopharmaceutical company, today announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with ...
Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback